News

Quadrivalent HPV vaccine treats recalcitrant warts in preadolescent children


 

References

A quadrivalent human papillomavirus vaccine was effective at removing therapy-resistant warts from children aged 9-11 years, according to Dr. Dietrich Abeck in private practice in Munich and Dr. Regina Fölster-Holst of the University Kiel, Lübeck, Germany.

The study group of six children had therapy-resistant warts for at least 2 years, with topical salicylic acid, duct tape occlusion therapy, and cryotherapy failing for all patients either alone or in combination. Patients received three doses of vaccines, with one patient becoming wart-free after the first treatment, four patients becoming disease-free after the second treatment, and the last patient becoming disease-free shortly after receiving the third vaccination.

The only reported side effect was temporary local swelling. The treatment with quadrivalent vaccine seemed to only work with young children, as only three of six patients aged 14-17 years saw results from the treatment, and three out of four adults saw no benefit from the vaccination.

“The rapid response observed shows that vaccination with the quadrivalent HPV vaccine has the ability to become an elegant, well-tolerated therapy for recalcitrant warts in children,” the investigators concluded.

Find the full study in Acta Dermato-Venereologica (doi: 10.2340/00015555-2111).

lfranki@frontlinemedcom.com

Recommended Reading

VIDEO: Flu shot lowered hospitalization risk for influenza pneumonia
MDedge Infectious Disease
Repeat Tdap vaccination is safe in pregnancy
MDedge Infectious Disease
ACIP updates immunization schedules for children, adolescents
MDedge Infectious Disease
ACIP recommends changes to 2016 adult immunization schedule
MDedge Infectious Disease
No flu vaccine for patients with egg allergy?
MDedge Infectious Disease
C. difficile risk score identifies high-risk patients
MDedge Infectious Disease
Statins may inhibit flu vaccine response
MDedge Infectious Disease
HPV vaccine uptake rising, but still low for male teens
MDedge Infectious Disease
Genomic sequencing technology reveals weakness in malaria vaccine
MDedge Infectious Disease
Oral H. pylori vaccine found effective, safe
MDedge Infectious Disease